Iasocholine (Fluorocholine (18f) Chloride)

Fluorocholine (18F) chloride is taken up by choline transporters on cell membranes and phosphorylated by choline kinase. This leads to accumulation in cells that are actively synthesizing phospholipids, such as malignant prostate cells, which can then be visualized on PET scans.

The administered activity of Iasocholine is determined by the prescribing physician or nuclear medicine specialist based on patient weight, imaging protocol, and regulatory guidelines. No fixed dose is provided in public literature.

Safety data for Fluorocholine (18F) chloride in pregnancy and lactation are limited. It should be avoided unless the diagnostic benefit outweighs potential risks, and breastfeeding should be paused for an appropriate period after administration.

To request Iasocholine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Iasocholine targets choline metabolism, whereas alternatives such as 68Ga‑PSMA focus on prostate‑specific membrane antigen expression. Choice of tracer depends on clinical objectives, availability, and local regulatory approval; Iasocholine offers high sensitivity for detecting lesions with elevated phospholipid synthesis.

Iasocholine must be stored refrigerated at 2‑8 °C, protected from light, and kept in its original shielding container. It should not be frozen or shaken, and any unused portion should be discarded according to local radiation safety regulations.

Iasocholine is administered intravenously by a qualified healthcare professional. The injection is typically performed in a controlled environment such as a nuclear medicine suite, followed by a waiting period before PET imaging to allow tracer distribution.

Serious risks include allergic reactions ranging from urticaria to anaphylaxis, severe hypotension, and radiation‑related tissue injury at the injection site. Patients should be monitored during and after administration for any adverse events.

Iasocholine is contraindicated in patients with known severe allergy to choline‑based compounds, those who are pregnant unless essential, and individuals with uncontrolled severe renal impairment where tracer clearance may be compromised.